{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:19:01Z","timestamp":1790907541908,"version":"4.1.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403193"],"award-info":[{"award-number":["82403193"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015956","name":"Special Project for Research and Development in Key Areas of Guangdong Province","doi-asserted-by":"publisher","award":["2025B03J0029"],"award-info":[{"award-number":["2025B03J0029"]}],"id":[{"id":"10.13039\/501100015956","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["25hytd009"],"award-info":[{"award-number":["25hytd009"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["2024MS001"],"award-info":[{"award-number":["2024MS001"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002402","name":"Sun Yat-Sen University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002402","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ctrv.2026.103108","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:41:22Z","timestamp":1770914482000},"page":"103108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Circulating tumor DNA in breast cancer: From technological foundation to clinical implementation"],"prefix":"10.1016","volume":"144","author":[{"given":"Xinyi","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8457-8421","authenticated-orcid":false,"given":"Yunjian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2026.103108_b0005","article-title":"Circulating tumor DNA: from discovery to clinical application in breast cancer","volume":"15","author":"Xu","year":"2024","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103108_b0010","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2026.103108_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217574","article-title":"The biological and technical challenges facing utilizing circulation tumor DNA in non-metastatic breast cancer patients","volume":"616","author":"Zeng","year":"2025","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103108_b0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s43556-025-00257-8","article-title":"Liquid biopsies in cancer","volume":"6","author":"Yin","year":"2025","journal-title":"Mol Biomed"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103108_b0025","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1146\/annurev-med-100223-090016","article-title":"Circulating tumor DNA: a pan-cancer biomarker in solid tumors with prognostic and predictive value","volume":"76","author":"Hitchen","year":"2025","journal-title":"Annu Rev Med"},{"issue":"579","key":"10.1016\/j.ctrv.2026.103108_b0030","article-title":"TP53 apoptosis biomarkers in breast cancer","volume":"15","author":"Rafeeq","year":"2026","journal-title":"Clin Chim Acta"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103108_b0035","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ccell.2023.04.008","article-title":"Clinical significance and biology of circular tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy","volume":"41","author":"Magbanua","year":"2023","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103108_b0040","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/jnci\/djad080","article-title":"Copy number aberrations in circulation tumor DNA enables prognosis prediction and molecular characterization of breast cancer","volume":"115","author":"Kim","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103108_b0045","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/clinchem\/hvab274","article-title":"Error characterization and statistical modeling improves circulating tumor DNA detection by droplet digital PCR","volume":"68","author":"Henriksen","year":"2022","journal-title":"Clin Chem"},{"key":"10.1016\/j.ctrv.2026.103108_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102642","article-title":"ESR1 mutations in HR+\/HER2-metastatic breast cancer: enhancing the accuracy of ctDNA testing","volume":"121","author":"Venetis","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103108_b0055","doi-asserted-by":"crossref","first-page":"8520","DOI":"10.3390\/ijms24108520","article-title":"A case-control study by ddPCR of ALU 260\/111 and LINE-1 266\/97 copy number ratio in circulating cell-free DNA in plasma revealed LINE-1 266\/97 as a potential biomarker for early breast cancer detection","volume":"24","author":"Bortul","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103108_b0060","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1373\/clinchem.2016.262337","article-title":"Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer","volume":"63","author":"Riva","year":"2017","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103108_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102235","article-title":"Rational thresholding of circular tumor DNA concentration for improved surveillance of metastatic breast cancer","volume":"9","author":"Martens","year":"2024","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103108_b0070","first-page":"195","article-title":"Circulating tumor DNA and its role in detection, prognosis and therapeutics of hepatocellular carcinoma","volume":"36","author":"Rashid","year":"2024","journal-title":"Chin J Cancer Res Chung-Kuo Yen Cheng Yen Chiu"},{"key":"10.1016\/j.ctrv.2026.103108_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2021.122220","article-title":"Circulating tumor DNA analysis for tumor diagnosis","volume":"228","author":"Wang","year":"2021","journal-title":"Talanta"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103108_b0080","article-title":"Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer","volume":"3","author":"Kazmi","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103108_b0085","doi-asserted-by":"crossref","first-page":"34","DOI":"10.7150\/jca.100922","article-title":"Technical and biological biases in bulk transcriptomic data mining for cancer research","volume":"16","author":"Liu","year":"2025","journal-title":"J Cancer"},{"key":"10.1016\/j.ctrv.2026.103108_b0090","article-title":"DNA methylation in esophageal cancer: technological advances and early detection clinical applications","volume":"15","author":"Tang","year":"2025","journal-title":"Front Oncol"},{"issue":"19","key":"10.1016\/j.ctrv.2026.103108_b0095","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1158\/1078-0432.CCR-24-1073","article-title":"Elacestrant in ER+, HER2- metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4\/6 inhibitor and in clinical subgroups","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103108_b0100","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circular tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.ctrv.2026.103108_b0105","article-title":"Predictive effectiveness of circulating tumor DNA in recurrent early-stage non-small cell lung cancer: an updated meta-analysis","volume":"9","author":"Lu","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103108_b0110","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13148-024-01646-6","article-title":"Prediction of methylation status using WGS data of plasma cfDNA for multi-cancer early detection (MCED). Clin","volume":"16","author":"Cui","year":"2024","journal-title":"Epigenetics"},{"issue":"10409","key":"10.1016\/j.ctrv.2026.103108_b0115","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/S0140-6736(23)01700-2","article-title":"Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study","volume":"402","author":"Schrag","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103108_b0120","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1002\/mco2.134","article-title":"Whole-genome circulating tumor DNA methylation landscape reveals sensitive biomarkers of breast cancer","volume":"3","author":"Hai","year":"2022","journal-title":"MedComm"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103108_b0125","doi-asserted-by":"crossref","first-page":"e1014","DOI":"10.1002\/ctm2.1014","article-title":"Whole-genome bisulfite sequencing analysis of circularizing tumour DNA for the detection and molecular classification of cancer","volume":"12","author":"Gao","year":"2022","journal-title":"Clin Transl Med"},{"issue":"49","key":"10.1016\/j.ctrv.2026.103108_b0130","doi-asserted-by":"crossref","first-page":"16709","DOI":"10.1021\/acs.analchem.1c04466","article-title":"In situ electrical monitoring of methylated DNA based on its conformational change to G-quadruplex using a solution-gated field-effect transistor","volume":"93","author":"Kim","year":"2021","journal-title":"Anal Chem"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103108_b0135","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/clinchem\/hvac086","article-title":"Single-molecule sequencing enables long cell-free DNA detection and direct methylation analysis for cancer patients","volume":"68","author":"Choy","year":"2022","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103108_b0140","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1101\/gr.265306.120","article-title":"Nondestructive energy deamination enables single-molecule long-read amplicon sequencing for the determination of 5-methylcytosine and 5-hydroxymethylcytosine at single-base resolution","volume":"31","author":"Sun","year":"2021","journal-title":"Genome Res"},{"issue":"15","key":"10.1016\/j.ctrv.2026.103108_b0145","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.1158\/1078-0432.CCR-21-0110","article-title":"Tumor-Na\u00efve multimodal profiling of circulating tumor DNA in head and neck squamous cell carcinoma","volume":"27","author":"Burgener","year":"2021","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"7732","key":"10.1016\/j.ctrv.2026.103108_b0150","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41586-018-0703-0","article-title":"Sensitive tumour detection and classification using plasma cell-free DNA methylomes","volume":"563","author":"Shen","year":"2018","journal-title":"Nature"},{"issue":"33","key":"10.1016\/j.ctrv.2026.103108_b0155","doi-asserted-by":"crossref","first-page":"18343","DOI":"10.1021\/acs.analchem.5c03822","article-title":"Multiple loci DNA methylation profiling for rapid colorectal cancer diagnosis based on a smartphone-integrated microfluidic biosensing platform","volume":"97","author":"Cai","year":"2025","journal-title":"Anal Chem"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103108_b0160","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s13206-024-00183-x","article-title":"CRISPR\/Cas-based nanobiosensor using plasmonic nanomaterials to detect disease biomarkers","volume":"19","author":"Choi","year":"2025","journal-title":"BioChip J"},{"issue":"21","key":"10.1016\/j.ctrv.2026.103108_b0165","article-title":"Gold nanomaterials-implemented CRISPR-Cas systems for biosensing","volume":"19","author":"Fu","year":"2023","journal-title":"Small Weinh Bergstr Ger"},{"issue":"20","key":"10.1016\/j.ctrv.2026.103108_b0170","doi-asserted-by":"crossref","first-page":"12781","DOI":"10.1021\/acsnano.3c12266","article-title":"Ultrasensitive and rapid circulating tumor DNA liquid biopsy using surface-confined gene amplification on dispersible magnetic nano-electrodes","volume":"18","author":"Park","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.ctrv.2026.103108_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2020.112821","article-title":"CRISPR\/Cas9 clevacuated triggered ESDR for circular tumor DNA detection based on a 3D graphene\/AuPtPd nanoflower biosensor","volume":"173","author":"Chen","year":"2021","journal-title":"Biosens Bioelectron"},{"key":"10.1016\/j.ctrv.2026.103108_b0180","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202507126","article-title":"Engineered crRNA drives RPA-T7-CRISPR\/Cas14a cascade for ultrasensitive detection of ctDNA PIK3CA H1047R","author":"Yu","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.ctrv.2026.103108_b0185","article-title":"Explainable machine learning reveals ribosome biogenesis biomarkers in preeclampsia risk prediction","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103108_b0190","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006284","article-title":"Genomic approaches to cancer and minimal residual disease detection using circular tumor DNA","volume":"11","author":"Semenkovich","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103108_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105286","article-title":"Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circular tumor DNA in early-stage breast cancer","volume":"10","author":"Elliott","year":"2025","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103108_b0200","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.canlet.2005.11.027","article-title":"Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients","volume":"243","author":"Huang","year":"2006","journal-title":"Cancer Lett"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103108_b0205","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1002\/mco2.766","article-title":"Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges","volume":"5","author":"Li","year":"2024","journal-title":"MedComm"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103108_b0210","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1186\/s12967-025-06495-2","article-title":"DNA methylation in breast cancer: early detection and biomarker discovery through current and emerging approaches","volume":"23","author":"Hum","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.ctrv.2026.103108_b0215","doi-asserted-by":"crossref","DOI":"10.37349\/etat.2025.1002314","article-title":"The development and applications of circulating tumour cells, circulating tumour DNA and other emerging biomarkers for early cancer detection","volume":"6","author":"Thomas Junior","year":"2025","journal-title":"Explor Target Antitumor Ther"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103108_b0220","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.ctrv.2026.103108_b0225","doi-asserted-by":"crossref","DOI":"10.1097\/CCO.0000000000001180","article-title":"Circulating tumor DNA in early-stage triple-negative breast cancer: clinical landscape and key open challenges","author":"De Placido","year":"2025","journal-title":"Curr Opin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103108_b0230","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1038\/s41591-025-03725-4","article-title":"Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial","volume":"31","author":"Mittendorf","year":"2025","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103108_b0235","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.annonc.2023.08.004","article-title":"Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030","volume":"34","author":"Parsons","year":"2023","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103108_b0240","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ccell.2023.04.008","article-title":"Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy","volume":"41","author":"Magbanua","year":"2023","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103108_b0245","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.annonc.2022.11.005","article-title":"Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer","volume":"34","author":"Turner","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103108_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100312","article-title":"Liquid biopsy in breast cancer: redefining precision medicine","volume":"9","author":"Schiavone","year":"2025","journal-title":"J Liq Biopsy."},{"issue":"1","key":"10.1016\/j.ctrv.2026.103108_b0255","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41523-024-00626-6","article-title":"Circulating tumor DNA validity and potential uses in metastatic breast cancer","volume":"10","author":"Amato","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103108_b0260","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.annonc.2022.09.163","article-title":"Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study","volume":"34","author":"Reichert","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103108_b0265","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1158\/1078-0432.CCR-22-2128","article-title":"Evaluation of a liquid biopsy-breast cancer methylation (LBx-BCM) cartridge assay for predicting early disease progression and survival: TBCRC 005 prospective trial","volume":"29","author":"Visvanathan","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103108_b0270","first-page":"63","article-title":"Circulating tumor DNA as prognostic markers of relaxed breast cancer: a systematic review and meta-analysis","volume":"4","author":"Guo","year":"2024","journal-title":"J Natl Cancer Cent"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103108_b0275","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ctrv.2026.103108_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101237","article-title":"Clinical applications of circular tumor DNA in hematological malignancy: from past to the future","volume":"68","author":"Li","year":"2024","journal-title":"Blood Rev"},{"key":"10.1016\/j.ctrv.2026.103108_b0285","article-title":"Prognostic significance of circular tumor DNA in urothelial carcinoma patients undergoing immuno checkpoint inhibitor therapy: a systematic review and meta-analysis","volume":"16","author":"Ma","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2026.103108_b0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104427","article-title":"Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+\/HER2- metastatic breast cancer","volume":"201","author":"Guerini-Rocco","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103108_b0295","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.151851","article-title":"Targeting ESR1 mutation-induced transcriptional addition in breast cancer with BET inhibition","volume":"7","author":"Udden","year":"2022","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103108_b0300","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41523-022-00424-y","article-title":"Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR","volume":"8","author":"Ahn","year":"2022","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.ctrv.2026.103108_b0305","article-title":"Noninvasive detection of polyclonal acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations","volume":"5","author":"Varghese","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103108_b0310","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/14737140.2025.2479604","article-title":"Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4\/6 inhibitors","volume":"25","author":"Sahin","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103108_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104296","article-title":"Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circular tumor DNA assay","volume":"10","author":"Janni","year":"2025","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103108_b0320","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/1078-0432.CCR-21-3276","article-title":"Clinical significance of PIK3CA and ESR1 Mutations in circulating tumor DNA: analysis from the MONARCH 2 study of abemaciclib plus fulvestrant","volume":"28","author":"Tolaney","year":"2022","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103108_b0325","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1-mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med."},{"issue":"4","key":"10.1016\/j.ctrv.2026.103108_b0330","first-page":"343","article-title":"Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive\/HER-2-negative breast cancer","volume":"34","author":"Lyu","year":"2022","journal-title":"Chin J Cancer Res Chung-Kuo Yen Cheng Yen Chiu"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103108_b0335","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41416-022-02021-z","article-title":"PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer","volume":"128","author":"Shi","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2026.103108_b0340","article-title":"Impact of circulating tumor DNA-based detection of molecular residual disease on the conduct and design of clinical trials for solid tumors","volume":"6","author":"Kasi","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103108_b0345","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/clinchem\/hvac121","article-title":"Circulating tumor DNA as a biomarker for monitoring patients with solid cancers: comparison with standard protein biomarkers","volume":"68","author":"Duffy","year":"2022","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103108_b0350","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41523-024-00708-5","article-title":"Adjuvant endocrine therapy with cyclin-dependent kinase 4\/6 inhibitor, ribociclib, for localized hormone receptor-positive\/HER2- breast cancer (LEADER)","volume":"11","author":"Spring","year":"2025","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103108_b0355","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10549-024-07508-2","article-title":"Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer","volume":"209","author":"Garcia-Murillas","year":"2025","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103108_b0360","first-page":"153","article-title":"The prognostic role of circularizing tumor DNA across breast cancer molecular subtypes: a systematic review and meta-analysis","volume":"4","author":"Guo","year":"2024","journal-title":"J Natl Cancer Cent"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103108_b0365","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.annonc.2025.01.021","article-title":"Whole genome sequencing-powered ctDNA sequencing for breast cancer detection","volume":"36","author":"Garcia-Murillas","year":"2025","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103108_b0370","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1158\/2159-8290.CD-21-0634","article-title":"Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease","volume":"11","author":"Moding","year":"2021","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103108_b0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102390","article-title":"Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis","volume":"9","author":"Nader-Marta","year":"2024","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103108_b0380","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ccell.2023.04.008","article-title":"Clinical significance and biology of circular tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy","volume":"41","author":"Magbanua","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2026.103108_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2024.116611","article-title":"Triple quenching effect of nanozyme catalyzed precipitation combined with energy-free amplification for photoelectrochemical biosensing of circular tumor DNA","volume":"263","author":"Li","year":"2024","journal-title":"Biosens Bioelectron"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103108_b0390","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13058-025-02024-7","article-title":"Advances in CTC and ctDNA detection techniques: opportunities for improving breast cancer care","volume":"27","author":"Zhong","year":"2025","journal-title":"Breast Cancer Res BCR"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103108_b0395","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/10408363.2023.2230290","article-title":"Pre-analytical conditions and implementation of quality control steps in liquid biopsy analysis","volume":"60","author":"Ntzifa","year":"2023","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103108_b0400","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/ijc.33312","article-title":"Prognostic significance of postsurgery circulation tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies","volume":"148","author":"Tie","year":"2021","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103108_b0405","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1158\/1078-0432.CCR-24-3145","article-title":"Detection of circulating tumor DNA using a tissue-free epigenomic assay is a highly prognostic biomarker in early-stage triple-negative breast cancer","volume":"31","author":"Ademuyiwa","year":"2025","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103108_b0410","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41416-022-02017-9","article-title":"The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis","volume":"128","author":"Faulkner","year":"2023","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103108_b0415","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1158\/1078-0432.CCR-23-2326","article-title":"Comparison of circulating tumor DNA assays for molecular residual disease detection in early-stage triple-negative breast cancer","volume":"30","author":"Coakley","year":"2024","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103108_b0420","first-page":"6","article-title":"Chinese quality control indices for standardized diagnosis and treatment of renal cancer (2022 edition)","volume":"4","author":"Yao","year":"2024","journal-title":"J Natl Cancer Cent"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103108_b0425","first-page":"623","article-title":"Chinese quality control indices for standardized diagnosis and treatment of gastric cancer (2022 edition)","volume":"34","author":"Li","year":"2022","journal-title":"Chin J Cancer Res Chung-Kuo Yen Cheng Yen Chiu"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103108_b0430","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1021\/acsbiomaterials.4c00606","article-title":"Recent advancements in the application of circulating tumor DNA as biomarkers for early detection of cancers","volume":"10","author":"Mishra","year":"2024","journal-title":"ACS Biomater Sci Eng"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103108_b0435","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1001\/jamainternmed.2023.3603","article-title":"Assessing the clinical utility of liquid biopsies across 5 potential indications from therapy selection to population screening: a review","volume":"183","author":"Carr","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103108_b0440","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1038\/s41467-021-22463-y","article-title":"Tissue-specific cell-free DNA degradation quantifies circular tumor DNA burden","volume":"12","author":"Zhu","year":"2021","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103108_b0445","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2024.1270","article-title":"Budget impact analysis of circulating tumor DNA testing for colon cancer in commercial health and medicare advantage plans","volume":"5","author":"Li","year":"2024","journal-title":"JAMA Health Forum"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103108_b0450","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41523-024-00653-3","article-title":"Use of ctDNA in early breast cancer: analytical validity and clinical potential","volume":"10","author":"Panet","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103108_b0455","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-24-3472","article-title":"Ultrasensitive detection and monitoring of circulating tumor DNA using structural variants in early-stage breast cancer","volume":"31","author":"Elliott","year":"2025","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103108_b0460","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/clinchem\/hvad188","article-title":"A practical approach to interpreting circulating tumor DNA in the management of gastrointestinal cancers","volume":"70","author":"Allan","year":"2024","journal-title":"Clin Chem"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103108_b0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103990","article-title":"Collagen signature adds prognostically significant information to staging for breast cancer","volume":"9","author":"Li","year":"2024","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103108_b0470","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.2024024371","article-title":"EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma","volume":"144","author":"Landgren","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103108_b0475","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1200\/JCO-24-02020","article-title":"Minimal residual disease-based end point for accelerated assessment of clinical trials in multiple myeloma: a pooled analysis of individual patient data from multiple randomized trials","volume":"43","author":"Shi","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103108_b0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103781","article-title":"The current staging and classification systems of breast cancer and their pitfalls: is it possible to integrate the complexity of this neoplasm into a unified staging system?","volume":"178","author":"da Luz","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103108_b0485","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.3390\/cancers14061430","article-title":"Biological characterization and clinical relevance of circulating tumor cells: opening the pandora\u2019s box of multiple myeloma","volume":"14","author":"Garc\u00e9s","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103108_b0490","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41523-025-00811-1","article-title":"Bridgening the gap: ctDNA, genomics, and equity in breast cancer care","volume":"11","author":"Aronson","year":"2025","journal-title":"npj Breast Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103108_b0495","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41467-023-36801-9","article-title":"Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer","volume":"14","author":"Prat","year":"2023","journal-title":"Nat Commun"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:35:59Z","timestamp":1773041759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":99,"alternative-id":["S0305737226000228"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103108","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating tumor DNA in breast cancer: From technological foundation to clinical implementation","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103108","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103108"}}